Stockscreener 앱 받기
43.58
0.00%
0.00
시간 외 거래:
43.58
전일 마감가:
$43.58
열려 있는:
$43.37
하루 거래량:
541.92K
Relative Volume:
0.86
시가총액:
$2.53B
수익:
$776.83M
순이익/손실:
$-29.02M
주가수익비율:
-85.12
EPS:
-0.512
순현금흐름:
$82.25M
1주 성능:
-3.35%
1개월 성능:
-11.83%
6개월 성능:
-10.61%
1년 성능:
+34.82%
1일 변동 폭
$42.50
$44.01
1주일 범위
$42.45
$45.89
52주 변동 폭
$30.83
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
43.58 | 2.55B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
(SUPN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
SUPN Stock Price, Quote & Chart - ChartMill
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - MSN
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - AOL.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
Why Supernus Pharmaceuticals Shares Surged - AOL.com
Supernus Pharmaceuticals to present at June healthcare investor conferences - Pluang
Drugmaker Supernus heads to New York and Miami for June investor events - Stock Titan
Supernus Pharmaceuticals to Participate in June Investor Conferences - GlobeNewswire
How (SUPN) Movements Inform Risk Allocation Models - Stock Traders Daily
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 2026 Earnings: Robust EPS Beat Overshadowed by Mild Share DeclinePeak Earnings Alert - The League of Women Voters of Texas
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment By Investing.com - Investing.com Australia
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox
Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call HighlightsNews and Statistics - IndexBox
Trading Systems Reacting to (SUPN) Volatility - Stock Traders Daily
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
TradingKey - TradingKey
Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026 - Pluang
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed? - Sahm
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat
Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com
Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative - Sahm
SUPN Technical Analysis & Stock Price Forecast - Intellectia AI
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - Sahm
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - The Globe and Mail
Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth - IndexBox
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference - The Manila Times
Supernus offers May 12 webcast as CEO joins Bank of America event - Stock Titan
Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)? - Yahoo Finance
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55 - Moomoo
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2026 Earnings Call Transcript - Insider Monkey
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges - The Globe and Mail
Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN
Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Supernus Pharmaceuticals | 8-K: Supernus Announces First Quarter 2026 Financial Results - Moomoo
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings call transcript: Supernus Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Canada
Supernus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Supernus: Q1 Earnings Snapshot - WKYC
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
0.95%
1.13%
자본화:
|
볼륨(24시간):